Treated Site (N) | Change in grade | Baseline to End of RT n (%) | Baseline to End of follow-up n (%) | End of RT to End of follow-up n (%) |
---|---|---|---|---|
Uterovaginal (N=19) | Worsened | - | 1 (5.3%) | 2 (10.5%) |
No change | 1 (5.3%) | 1 (5.3%) | 10 (52.6%) | |
Improved | 18 (94.7%) | 15 (78.9%) | 5 (26.3%) | |
Missing | - | 2 (10.5%) | 2 (10.5%) | |
Bladder (N=17) | Worsened | - | 2 (11.8%) | 5 (29.4%) |
No change | 6 (35.3%) | 4 (23.5%) | 8 (47.1%) | |
Improved | 11 (64.7%) | 10 (58.8%) | 3 (17.6%) | |
Missing | - | 1 (5.9%) | 1 (5.9%) | |
Lung (N=10) | Worsened | - | - | - |
No change | - | - | 6 (60.0%) | |
Improved | 10 (100.0%) | 8 (80.0%) | 2 (20.0%) | |
Missing | - | 2 (20.0%) | 2 (20.0%) | |
Upper GI (N=10) | Worsened | 1 (10.0%) | 3 (30.0%) | 2 (20.0%) |
No change | - | - | 4 (40.0%) | |
Improved | 9 (90.0%) | 6 (60.0%) | 3 (30.0%) | |
Missing | - | 1 (10.0%) | 1 (10.0%) | |
Other (N=6)* | Worsened | - | - | - |
No change | - | - | 5 (83.3%) | |
Improved | 6 (100.0%) | 6 (100.0%) | 1 (16.7%) |